Cargando…

Repurposing of a clinically used anti-HPV agent to prevent and treat SARS-CoV-2 infection as an intranasal formulation

Detalles Bibliográficos
Autores principales:	Hua, Chen, Ma, Qinhai, Zhu, Yun, Xia, Shuai, Liu, Zezhong, Li, Lin, Lu, Lu, Zhong, Nanshan, Liu, Shuwen, Yang, Zifeng, Jiang, Shibo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8390030/ https://www.ncbi.nlm.nih.gov/pubmed/34446694 http://dx.doi.org/10.1038/s41392-021-00737-7

Ejemplares similares

Inefficiency of Sera from Mice Treated with Pseudotyped SARS-CoV to Neutralize 2019-nCoV Infection
por: Liu, Zezhong, et al.
Publicado: (2020)

High-throughput screening of mutations affecting SARS-CoV-2 spike functions
por: Xia, Shuai, et al.
Publicado: (2023)

Application of “B+1” heterologous boosting strategy for preventing infection of SARS-CoV-2 variants with resistance to broad-spectrum coronavirus vaccines
por: Liu, Zezhong, et al.
Publicado: (2023)

Intranasal application of polyethyleneimine suppresses influenza virus infection in mice
por: He, Biao, et al.
Publicado: (2016)

Protective Effect of Intranasal Regimens Containing Peptidic Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor Against MERS-CoV Infection
por: Channappanavar, Rudragouda, et al.
Publicado: (2015)

Intranasally administered peptidic viral fusion inhibitor protected hDPP4 transgenic mice from MERS-CoV infection
por: Jiang, Shibo, et al.
Publicado: (2015)

Drug repurposing: Discovery of troxipide analogs as potent antitumor agents
por: Lu, Nan, et al.
Publicado: (2020)

Potent MERS-CoV Fusion Inhibitory Peptides Identified from HR2 Domain in Spike Protein of Bat Coronavirus HKU4
por: Xia, Shuai, et al.
Publicado: (2019)

An engineered recombinant protein containing three structural domains in SARS-CoV-2 S2 protein has potential to act as a pan-human coronavirus entry inhibitor or vaccine antigen
por: Wang, Xinling, et al.
Publicado: (2023)

Retraction Note to: SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion
por: Wang, Xinling, et al.
Publicado: (2020)

RETRACTED ARTICLE: SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion
por: Wang, Xinling, et al.
Publicado: (2020)

The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin
por: Xia, Shuai, et al.
Publicado: (2020)

A Five-Helix-Based SARS-CoV-2 Fusion Inhibitor Targeting Heptad Repeat 2 Domain against SARS-CoV-2 and Its Variants of Concern
por: Xing, Lixiao, et al.
Publicado: (2022)

Double insult: flu bug enhances SARS-CoV-2 infectivity
por: Su, Shan, et al.
Publicado: (2021)

Up or down: where comes Omicron?
por: Liu, Zezhong, et al.
Publicado: (2022)

3-Hydroxyphthalic Anhydride-Modified Chicken Ovalbumin as a Potential Candidate Inhibits SARS-CoV-2 Infection by Disrupting the Interaction of Spike Protein With Host ACE2 Receptor
por: Liang, Taizhen, et al.
Publicado: (2021)

Intranasal Administration of Maleic Anhydride-Modified Human Serum Albumin for Pre-Exposure Prophylaxis of Respiratory Syncytial Virus Infection
por: Sun, Zhiwu, et al.
Publicado: (2015)

The putative mechanism of lymphopenia in COVID-19 patients
por: Wang, Xinling, et al.
Publicado: (2022)

Design and Efficacy of Nanogels Formulations for Intranasal Administration
por: Aderibigbe, Blessing A., et al.
Publicado: (2018)

Formulations for Intranasal Delivery of Pharmacological Agents to Combat Brain Disease: A New Opportunity to Tackle GBM?
por: van Woensel, Matthias, et al.
Publicado: (2013)

Urgent development of effective therapeutic and prophylactic agents to control the emerging threat of Middle East respiratory syndrome (MERS)
por: Lu, Lu, et al.
Publicado: (2015)

RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response
por: Liu, Zezhong, et al.
Publicado: (2020)

Development and in vivo evaluation of intranasal formulations of parathyroid hormone (1-34)
por: Wang, Dan, et al.
Publicado: (2021)

Intranasal dexmedetomidine is an effective sedative agent for electroencephalography in children
por: Chen, Hang, et al.
Publicado: (2020)

Intranasal Protollin Formulated Recombinant SARS-CoV S Protein Elicits Respiratory and Serum Neutralizing Antibodies
por: Barnard, Dale, et al.
Publicado: (2007)

Network-based drug repurposing for HPV-associated cervical cancer
por: Ahmed, Faheem, et al.
Publicado: (2023)

Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies
por: Wang, Shujing, et al.
Publicado: (2015)

A Toxin-Conjugated Recombinant Protein Targeting gp120 and gp41 for Inactivating HIV-1 Virions and Killing Latency-Reversing Agent-Reactivated Latent Cells
por: Wang, Xinling, et al.
Publicado: (2022)

Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2)
por: Runfeng, Li, et al.
Publicado: (2020)

Dual targeting powder formulation of antiviral agent for customizable nasal and lung deposition profile through single intranasal administration
por: Seow, Han Cong, et al.
Publicado: (2022)

Formulation and kinetic modeling of curcumin loaded intranasal mucoadhesive microemulsion
por: Patel, Mikesh B., et al.
Publicado: (2012)

Repurposing carrimycin as an antiviral agent against human coronaviruses, including the currently pandemic SARS-CoV-2
por: Yan, Haiyan, et al.
Publicado: (2021)

Repurposing ibuprofen-loaded microemulsion for the management of Alzheimer’s disease: evidence of potential intranasal brain targeting
por: Wen, Ming Ming, et al.
Publicado: (2021)

Liushen Capsules, a promising clinical candidate for COVID-19, alleviates SARS-CoV-2-induced pulmonary in vivo and inhibits the proliferation of the variant virus strains in vitro
por: Ma, Qinhai, et al.
Publicado: (2022)

Repurposing Thioridazine (TDZ) as an anti-inflammatory agent
por: Baig, Mirza S., et al.
Publicado: (2018)

Corrigendum to: Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2) [Pharmacol. Res. 156 (2020) 104761]
por: Runfeng, Li, et al.
Publicado: (2021)

Efficacy and safety of ReDuNing injection as a treatment for COVID-19 and its inhibitory effect against SARS-CoV-2
por: Ma, Qinhai, et al.
Publicado: (2021)

Repurposing Tranexamic Acid as an Anticancer Agent
por: Law, Mary E., et al.
Publicado: (2022)

Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages
por: Xia, Shuai, et al.
Publicado: (2022)

Drug repurposing strategies in the development of potential antifungal agents
por: Zhang, Qian, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_n2a532pdcck8cj73qfh6kim307